Modeling of cancer virotherapy with recombinant measles viruses.

The Edmonston vaccine strain of measles virus has potent and selective activity against a wide range of tumors. Tumor cells infected by this virus or genetically modified strains express viral proteins that allow them to fuse with neighboring cells to form syncytia that ultimately die. Moreover, infected cells may produce new virus particles that proceed to infect additional tumor cells. We present a model of tumor and virus interactions based on established biology and with proper accounting of the free virus population. The range of model parameters is estimated by fitting to available experimental data. The stability of equilibrium states corresponding to complete tumor eradication, therapy failure and partial tumor reduction is discussed. We use numerical simulations to explore conditions for which the model predicts successful therapy and tumor eradication. The model exhibits damped, as well as stable oscillations in a range of parameter values. These oscillatory states are organized by a Hopf bifurcation.

[1]  F. Khuri,et al.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Barrett,et al.  Inhibition of In Vitro Leukocyte Proliferation by Morbilliviruses , 2002, Journal of Virology.

[3]  Zeljko Bajzer,et al.  Mathematical modeling of cancer radiovirotherapy. , 2006, Mathematical biosciences.

[4]  James P. Freyer,et al.  Tumor growthin vivo and as multicellular spheroids compared by mathematical models , 1994, Bulletin of mathematical biology.

[5]  S. Russell,et al.  Antibody-targeted cell fusion , 2004, Nature Biotechnology.

[6]  F. Brauer,et al.  Mathematical Models in Population Biology and Epidemiology , 2001 .

[7]  J. Marshall,et al.  Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Vile,et al.  Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. , 2001, Blood.

[9]  L. Wein,et al.  Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. , 2002, Cancer research.

[10]  S. Russell,et al.  Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides , 2002, Nature Medicine.

[11]  G. Ahmann,et al.  Systemic therapy of myeloma xenografts by an attenuated measles virus. , 2001, Blood.

[12]  Helen Byrne,et al.  Modelling Avascular Tumour Growth , 2003 .

[13]  S. Russell,et al.  High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus , 2004, Cancer Research.

[14]  S. Russell.  RNA viruses as virotherapy agents , 2002, Cancer Gene Therapy.

[15]  Z Bajzer,et al.  Dynamics of multiple myeloma tumor therapy with a recombinant measles virus , 2009, Cancer Gene Therapy.

[16]  P. Mishra,et al.  Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. , 2003, Cancer research.

[17]  J. Ingle,et al.  A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer , 2006, Breast Cancer Research and Treatment.

[18]  D. Wodarz,et al.  Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.

[19]  L. Wein,et al.  Modeling and analysis of a virus that replicates selectively in tumor cells , 2001, Bulletin of mathematical biology.

[20]  Jianjun Paul Tian,et al.  Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. , 2006, Cancer research.

[21]  J S Spratt,et al.  Decelerating growth and human breast cancer , 1993, Cancer.

[22]  Luigi Preziosi,et al.  Cancer Modelling and Simulation , 2003 .

[23]  L. Wein,et al.  Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response , 2004, Bulletin of mathematical biology.

[24]  Z. Bajzer,et al.  Conceptual frameworks for mathematical modeling of tumor growth dynamics , 1996 .

[25]  D Liberati,et al.  Forecasting the growth of multicell tumour spheroids: implications for the dynamic growth of solid tumours , 2000, Cell proliferation.

[26]  Chetan Offord,et al.  A Hybrid Global Optimization Algorithm Involving Simplex and Inductive Search , 2001, International Conference on Computational Science.

[27]  S. Russell,et al.  Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model , 2006, Cancer Gene Therapy.

[28]  D. Sze,et al.  Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial , 2001, Gene Therapy.

[29]  S. Russell,et al.  Reengineering paramyxovirus tropism. , 2004, Virology.

[30]  Natalia L. Komarova,et al.  Computational Biology of Cancer: Lecture Notes and Mathematical Modeling , 2005 .

[31]  A. Dispenzieri,et al.  Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. , 2006, Experimental hematology.

[32]  D. Dingli,et al.  Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. , 2004, Blood.

[33]  Miljenko Huzak,et al.  Mathematical Modeling of Tumor Growth Kinetics , 1997 .

[34]  W. Bellini,et al.  Generation of defective interfering particles by two vaccine strains of measles virus. , 1996, Virology.

[35]  D. Dingli,et al.  Optimization of Tumor Virotherapy with Recombinant Measles Viruses , 2008 .

[36]  Lawrence M Wein,et al.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.

[37]  C. James,et al.  Rescue and propagation of fully retargeted oncolytic measles viruses , 2005, Nature Biotechnology.

[38]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[39]  D. Cameron,et al.  The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. , 2001, European journal of cancer.

[40]  Bard Ermentrout,et al.  Simulating, analyzing, and animating dynamical systems - a guide to XPPAUT for researchers and students , 2002, Software, environments, tools.

[41]  V. Lowe,et al.  Combined I-124 Positron Emission Tomography/Computed Tomography Imaging of NIS Gene Expression in Animal Models of Stably Transfected and Intravenously Transfected Tumor , 2005, Molecular Imaging and Biology.

[42]  R. Cattaneo,et al.  Efficiency of Measles Virus Entry and Dissemination through Different Receptors , 2002, Journal of Virology.

[43]  L. Hartmann,et al.  Intraperitoneal therapy of ovarian cancer using an engineered measles virus. , 2002, Cancer research.

[44]  Dominik Wodarz,et al.  Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. , 2003, Human gene therapy.

[45]  Y. Tao,et al.  The competitive dynamics between tumor cells, a replication-competent virus and an immune response , 2005, Journal of mathematical biology.

[46]  R. Martuza,et al.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions , 2001, Nature Medicine.